PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 19.11.2019 at 4:00 PM CET
Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2012101125) SPECIFIC ANTIBODIES AGAINST HUMAN CXCL4 AND USES THEREOF
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2012/101125 International Application No.: PCT/EP2012/051056
Publication Date: 02.08.2012 International Filing Date: 24.01.2012
IPC:
C07K 16/24 (2006.01) ,A61K 39/395 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
24
against cytokines, lymphokines or interferons
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Applicants:
INSERM (Institut National de la Santé et de la Recherche Médicale) [FR/FR]; 101 rue de Tolbiac F-75013 Paris, FR (AllExceptUS)
BIKFALVI, Andreas [FR/FR]; FR (UsOnly)
Inventors:
BIKFALVI, Andreas; FR
Agent:
HIRSCH, Denise; 7 rue Watt F-75013 Paris, FR
Priority Data:
11305068.624.01.2011EP
61/436,64627.01.2011US
Title (EN) SPECIFIC ANTIBODIES AGAINST HUMAN CXCL4 AND USES THEREOF
(FR) ANTICORPS SPÉCIFIQUES DIRIGÉS CONTRE LE CXCL4 HUMAIN ET LEURS UTILISATIONS
Abstract:
(EN) The invention relates to specific antibodies against human CXCL4 and uses thereof. More particularly,the antibodies of the invention maybe used for specifically detecting CXCL4 in a biological sample or as drug, for instance for treating disease associated with pathological angiogenesis when said antibodies are coupled with a cytotoxic agent.
(FR) La présente invention concerne des anticorps spécifiques dirigés contre le CXCL4 humain et leurs utilisations. Plus particulièrement, les anticorps selon l'invention peuvent être utilisés pour la détection spécifique de CXCL4 dans un échantillon biologique ou en tant que médicament pour le traitement de maladie associée à l'angiogenèse pathologique lorsque lesdits anticorps sont couplés à un agent cytotoxique.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)